Teva gets EU OK for Symbicort knockoff, is mentioned in Mylan, Actavis Celebrex suits; Will Teva get bigger?;

@FiercePharma: Looking for more megadeal excitement? Don't look at Sanofi, CEO says. Story | Follow @FiercePharma

@TracyStaton: Why pay $100B for AstraZeneca? Let Pfizer's CEO count the reasons. A biggie = "synergies," i.e. cost cuts. More | Follow @TracyStaton

@EricPFierce: The FDA is letting Baxter import saline from a plant in Spain to help ease the shortage in the US. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Allergan to propose to Shire again, but does Irish beauty want to get engaged? Article | Follow @CarlyHFierce

> Teva Pharmaceutical Industries ($TEVA) has gotten the OK from the EU to market its new DuoResp Spiromax multidose dry-powder inhaler, its knockoff of AstraZeneca's ($AZN) blockbuster Symbicort. Release

> Actavis ($ACT) has followed Mylan ($MYL) to court to sue the FDA for granting Teva Pharmaceutical Industries the exclusive generic rights to Pfizer's ($PFE) blockbuster painkiller Celebrex, which goes off patent in May. Story

> Teva may feel pressure to jump into the acquisition boom that has engulfed the pharma industry. Story

> Brazilian drugmaker and consumer goods producer, Hypermarcas, has been gaining market share in the the country by pushing its marketing in the face of a economic slump there. Story

> Massachusetts and other states are setting up a federal fight over FDA's approval of painkiller Zohydro with plans to restrict use even after a court order that they could not impede its use. Story

> Biogen Idec ($BIIB) announced new two-year data for drug candidate Plegridy, its peginterferon beta-1a, long-lasting treatment for relapsing forms of multiple sclerosis (RMS). Release

> Finnish drug maker Orion today reported Q1 an operating profit of €67 million ($93 million), missing analyst estimates but keeping its outlook for the year unchanged. Story

Medical Device News

@FierceMedDev: Luminex reports higher Q1 revenues despite earlier warnings. Article | Follow @FierceMedDev

@VarunSaxena2: Alere to sell stake in BBI Diagnostics Group subsidiary in bid to keep activist investor Coppersmith Capital Management at bay. | Follow @VarunSaxena2

@EmilyWFierce: It's a full menagerie in this week's issue of FierceBiotechResearch: Here's the issue | Follow @EmilyWFierce

@MichaelGFierce: ICYMI from FierceDrugDelivery: Imaging technique maps transdermal drug migration. More | Follow @MichaelGFierce

> Diagnostics firm Indi snags $47.3M for lung tests. More

> GE launches Alzheimer's imaging agent in a cloudy market. Report

> Boston Scientific swings to a profit amid its turnaround plan. Article

Biotech News

@FierceBiotech: Why would Pfizer want to buy AstraZeneca? It's not R&D. More | Follow @FierceBiotech

@JohnCFierce: And that PhII failure wasn't a failure. No sir. Not at all. It was a success. Because Concert says so. All perfectly clear now. | Follow @JohnCFierce

@DamianFierce: BMY's taking the rolling FDA submission approach with much-watched cancer drug nivolumab. Story | Follow @DamianFierce

@EmilyMFierce: Another chink in HIV's armor may point the way to a vaccine. More from FierceBiotech Research | Follow @EmilyMFierce

> Allergan woos J&J, Sanofi while keeping its eyes on Shire, per reports. News

> Amicus shares rally as a revised PhIII delivers positive Fabry data. More

> Bristol-Myers targets neurodegenerative diseases in $725M deal to buy iPierian. Story

Biotech Research News

> Another chink in HIV's armor may point the way to a vaccine. Article

> Protein found in naked mole rats could shed light on Alzheimer's, Parkinson's development. More

> Deadly MERS outbreak blamed on camels. Report

> Rutgers wins $26M NIH grant to help fill lackluster antibiotics pipeline. Report

> Preclinical study advances H. pylori vaccine for stomach cancer. Item

> Single molecule that targets both amyloid and tau could treat Alzheimer's. Story

Pharma Manufacturing News

> Sanofi supply-chain issues again put hurt on its earnings. News

> Baxter adds saline production from Spain to U.S. supply. Story

> FDA loses another top dog in quality to Mylan. Item

> Takeda snags another big subsidy for influenza vaccine plant in Japan. More

> Indian ban on Wockhardt plant lifted by top Indian regulator. Article

And Finally... Cambridge, MA-based MC10 hopes to help athletes of all kinds replicate their best moments with new high-performance electronics that measure biometrics like brain activity, body temperature and heart rate. Story

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.